In Silico Study of Histone Deacetylase Inhibitor as Anticancer Agents

Authors

  • PARIN Sidat SIDAT SHREE DHANVANTARY PHARMACY COLLEGE SURAT
  • Malleshappa N. Noolvi Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
  • Vishal G. Beldar Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
  • Azmin M. Mogal Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India

Abstract

The clinical selective histone deacetylase inhibitor vorinostat is most commonly used for the treatment of lymphoma and solid tumor and has been preventing lives worldwide. Vorinostat is used in both treatment and prevention of lymphoma and other tumors. Based on these for current study some vorinostat derivatives with thiadiazole moiety containing derivatives have been designed for in silico study. For present work, the already selected study was against histone human using PDB 4LXZ. Designed molecule showed docking interaction with active site amino acid by hydrogen bond as well as vanderwaal interaction. The information obtained from this study like, total energy, and interaction with amino acid suggested necessary binding interaction used to optimize lead molecule. These finding can be utilized for development of new anticancer agents with reduced side effect and minimal toxic effects.

 

Keywords: Vorinostat derivatives, HDAC inhibitor, anticancer agents


Cite this Article

Parin S. Sidat, Malleshappa N. Noolvi, Vishal G. Beldar, Azmin M. Mogal. In Silico Study of Histone Deacetylase Inhibitor as Anticancer Agents. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(2): 6–23p

Downloads

Published

2019-08-28

Issue

Vol. 6 No. 2 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.